Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.sleep.2011.06.013 | DOI Listing |
Front Neurol
July 2024
Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Introduction: Excessive daytime sleepiness (EDS) is a common and debilitating symptom in both forms of myotonic dystrophy (DM), significantly impacting patients' quality of life. The review focuses on the purpose of examining the current understanding of EDS in these conditions, the difficulty in correctly accessing it, the recent findings related to its etiology and prevalence, and a summary of potential therapeutic implications.
Methods: We conducted a comprehensive search through PubMed, selecting studies that provided significant insights into the mechanisms, prevalence, and management of EDS in DM1 and DM2.
Zh Nevrol Psikhiatr Im S S Korsakova
October 2022
State Scientific Center of the Russian Federation - Institute of Biomedical Problems of the Russian Academy of Sciences, Moscow, Russia.
Unlabelled: One of the main manifestations of excessive daytime sleepiness (EDS) among patients with Parkinson's disease is sudden-onset sleep (SOS). The SOS episodes could dramatically increase the traumatic ratio among those patients. The factors of SOS among PD patients are not well understood.
View Article and Find Full Text PDFCNS Neurol Disord Drug Targets
September 2020
Depto. de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
Background: Excessive daytime sleepiness and cataplexy are among the symptoms of narcolepsy, a sleep disorder caused by the loss of hypocretin/orexin (HCRT/OX) neurons placed into the Hypothalamus (LH). Several treatments for managing narcolepsy include diverse drugs to induce alertness, such as antidepressants, amphetamine, or modafinil, etc. Recent evidence has shown that cannabidiol (CBD), a non-psychotropic derived from Cannabis sativa, shows positive therapeutic effects in neurodegenerative disorders, including Parkinson´s disease.
View Article and Find Full Text PDFCurr Neurol Neurosci Rep
October 2018
System Medicine Department, University of Rome Tor Vergata, Rome, Italy.
Purpose Of Review: To update current knowledge regarding sleep disturbances and myotonic dystrophies so as to better understand if sleep symptoms may help in the early recognition of the two genetic subtypes: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).
Recent Findings: Sleep-disordered breathing (SDB), restless legs syndrome, periodic limb movements in sleep, hypersomnia, and REM sleep dysregulation are frequently described in DM1 patients. SDB does not always explain hypersomnia, but a central dysregulation of sleep-wake modulation is reported mainly in DM1.
Chronobiol Int
September 2018
a Departamento de Neurologia e Neurocirurgia , Universidade Federal de São Paulo , São Paulo , Brasil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!